Shire has forged an alliance with arGEN-X to discover and develop therapeutic antibody products using arGEN-X’s proprietary SIMPLE Antibody™ technology platform. arGEN-X will isolate and characterise human antibodies against rare genetic disease targets identified by Shire. Shire will then have the option to license the most promising leads for further preclinical and clinical development and global commercialisation. The deal will further supplement the pipeline of Shire’s Human Genetic Therapies division.